Fulcrum Therapeutics Q3 2026 Results: Net Loss of $10.9M, Loss Narrows
Fulcrum Therapeutics is currently pursuing a merger with Slate Medicines, Inc. while undergoing significant restructuring, including the cessation of clinical development for pociredir and a workforce reduction. The company reported a net loss of $56.0 million for the nine months ended September 30, 2026, and currently has no product candidates in active clinical development.
- Key figure
- Net loss $10.9M